2020 SOHO Updates on AlloHSCT in AML: Are There Benefits to Chemo in Older Adults? Should We Use CC-486 in the Maintenance Setting? What Are the Outcomes With Favorable Risk? Is Intensive Induction Always Necessary?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

2020 SOHO Updates on AlloHSCT in AML: Are There Benefits to Chemo in Older Adults? Should We Use CC-486 in the Maintenance Setting? What Are the Outcomes With Favorable Risk? Is Intensive Induction Always Necessary?

By Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020) FEATURING Uma Borate

111 views

November 13, 2020

0 Comments

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Treatment-Related Quality of Life in MF

Feat. A. Hunter

ASH 2023 Summary: "The Best of Acute Leukemia and MDS - Highlig…

Feat. T. Badar

21:05

Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale

50:34

Scripps MD Anderson Cancer Center

The Cure of Leukemias in the Next Decade: An Optimist’s View

Feat. H. Kantarjian

19:10

5th SOHO Italy Annual Conference

SOHO Italy 2023: How I Treat AML at MD Anderson Cancer Center

Feat. H. Kantarjian

12:36

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Myeloid for Measure - New Therapeutics in…

Feat. A. Patel

12:33

SOHO 2022 Tenth Annual Meeting

SOHO 2022 Next Questions: AML

Feat. H. Kantarjian

09:51

i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje

14:19

Talha Badar

Challenges in the Management of TP53-Mutated AML: Potential Strategi…

44:26

University of Colorado Division of Hematology

Novel Therapies in AML and MDS

Feat. D. Pollyea

22:30

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Emerging Treatment Options for AML in 2024

Feat. A. Perl

13:39

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Triplet Regimens in AML: Beyond Azacitidine + Venetoclax

Feat. C. DiNardo

14:39

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Immunotherapies in Acute Leukemias: 2024 Update

Feat. C. Lai

27:28

UChicago Medicine

AML: Current Treatment Landscape and Key Recent Updates

Feat. A. Patel

32:04

Moffitt Cancer Center

Experts Discuss the Latest Data in Myeloid Diseases

Feat. A. Kuykendall, R. Komrokji, O. Chan, D. Sallman

40:21

Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

Overview of Hematopoietic Cell Transplantation

Feat. R. Salit

15:45

SOHO 2022 Tenth Annual Meeting

SOHO 2022: How Do We Overcome Resistance to Venetoclax in AML

Feat. M. Konopleva

16:59

MyCancerHaven

Experts Discuss Current and Future Management of AML

Feat. R. Vij, N. Daver

18:48

Current Challenges in Hematology

Venetoclax-Based Combinations in Newly Diagnosed AML: A New Golden S…

Feat. C. DiNardo

06:23

ASH 2022 Conference Coverage

ASH 2022 Comparing Venetoclax & Azacitidine to Conventional Indu…

Feat. A. Fathi

16:11

MyCancerHaven

Experts Discuss the Use of Targeted Therapies in AML

Feat. R. Vij, E. Wang

Login

Login

Join VuMedi

2020 SOHO Updates on AlloHSCT in AML: Are There Benefits to Chemo in Older Adults? Should We Use CC-486 in the Maintenance Setting? What Are the Outcomes With Favorable Risk? Is Intensive Induction Always Necessary?

Related Content